pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ultragenyx Pharmaceutical Inc. ($RARE) · news · pharmadog
← back to Ultragenyx Pharmaceutical Inc.
News mentioning $RARE
836
stories
Jul 27, 26
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
stat
Jul 27, 26
STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
stat
Jul 27, 26
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
Jul 27, 26
A trend that isn’t fading, ultra-processed baby foods
stat
Jul 27, 26
STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease
stat
Jul 27, 26
Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease
endpoints
Jul 27, 26
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
fiercebiotech
Jul 27, 26
Opinion: How midwives like me can help fight medical misinformation
stat
Jul 27, 26
STAT+: As some medical schools embrace RFK Jr.’s nutrition push, they deftly sidestep MAHA priorities
stat
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 24, 26
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
stat
Jul 24, 26
Amgen shares new Tavneos analysis in effort to resolve FDA dispute
endpoints
Jul 24, 26
Amgen sheds around 40 staffers amid continuing struggles
fiercebiotech
Jul 24, 26
Ipsen’s Bylvay fails key trial in children with rare liver disease
endpoints
Jul 24, 26
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
Jul 24, 26
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
Jul 24, 26
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
biospace
Jul 24, 26
STAT+: Fatal gene-editing trial in China raises ethics and oversight questions
stat
Jul 24, 26
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
endpoints
Jul 24, 26
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
fiercebiotech
Jul 24, 26
Opinion: The U.S. pharmaceutical supply chain problem is not about China
stat
Jul 24, 26
Senate advances MAHA-friendly bill for food warning labels and junk food ad bans
stat
Jul 24, 26
Scribe secures $129M in a rare gene editing IPO
biopharma dive
Jul 23, 26
STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
stat
Jul 23, 26
STAT+: What’s in the last-minute flurry of health care bills?
stat
Jul 23, 26
FDA panel confronting peptide controversy
stat
Jul 23, 26
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
Jul 23, 26
From Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotech
fiercebiotech
Jul 23, 26
STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel
stat
Jul 23, 26
Make or break: Commercial hires critical for success
biospace
← prev
page 18 of 28
next →
